Drug Profile
Research programme: TNF-related apoptosis-inducing ligand receptor agonists - Apogenix
Alternative Names: APG-350; TRAIL receptor agonists - ApogenixLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Apogenix
- Class Recombinant fusion proteins
- Mechanism of Action TNF-related apoptosis-inducing ligand receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in Germany
- 09 Dec 2013 Research programme: TNF-related apoptosis-inducing ligand receptor agonists - Apogenix is available for licensing in World as of 09 Dec 2013. http://apogenix.com/
- 06 Apr 2011 Preclinical trials in Solid tumours in Germany (unspecified route)